135 CNS / Neurology CRO and CDMO vendors

What kind of CRO work does a CNS / Neurology program need?

CNS and neurology programs carry a problem most other therapeutic areas do not: the brain is walled off. The blood-brain barrier keeps most molecules out, so the first questions a vendor has to answer are whether your compound actually crosses into the central compartment and how much of it reaches the target tissue, not just the plasma. That single fact reshapes the whole outsourcing plan, from the DMPK assays you run to the readouts you trust, and it is why a generalist tox lab that is excellent at oncology can be the wrong partner here.

In discovery and preclinical, the work clusters around brain exposure and the right models. You need DMPK that measures CNS penetration (brain-to-plasma ratios, unbound brain concentration via equilibrium dialysis, P-glycoprotein efflux liability, CSF sampling), efflux and transporter panels, and where relevant a microdialysis study to track free drug in the brain over time. The pharmacology runs in disease-relevant animal models that differ by indication: transgenic and amyloid or tau models for Alzheimer's, MPTP and alpha-synuclein models for Parkinson's, kindling and chemoconvulsant models for epilepsy, EAE for multiple sclerosis, SOD1 and other models for ALS, and a battery of pain and neuropathy assays. Readouts lean on behavioral testing (Morris water maze, rotarod, open field, fear conditioning), electrophysiology (EEG, patch-clamp, MEA), histopathology and neuroinflammation markers, and increasingly imaging such as small-animal PET or MRI. Safety pharmacology has a CNS-specific edge too, since seizure liability and the FOB or Irwin neurobehavioral screen sit right in the core battery.

On the clinical side, CNS trials are operationally hard in ways that show up in the vendor you pick. Endpoints are often subjective rating scales (ADAS-Cog, CDR-SB, UPDRS or MDS-UPDRS, EDSS, MADRS, seizure diaries), so rater training, certification, and central review become real line items, not afterthoughts. Placebo response runs high in CNS, which raises the bar on site selection and monitoring. Biomarkers matter enormously: CSF assays for amyloid, tau and p-tau, neurofilament light chain (NfL) as a neurodegeneration marker, and PET imaging with amyloid, tau, or dopamine-transporter tracers, all of which need a central lab and imaging core that have run these assays before. You will also source clinical operations, biostatistics with experience handling these scales, a central lab, imaging vendors, pharmacovigilance, and clinical supply, often including formulation work for CNS delivery routes like intrathecal or intranasal administration. On the CDMO side, formulation and delivery for brain penetration (and for biologics, getting a large molecule past the barrier at all) is its own specialist conversation.

How do you choose a CRO for CNS / Neurology?

The deciding factor is genuine therapeutic-area depth, not a logo or the lowest bid. CNS is unforgiving of vendors learning on your dime, because the models are finicky, the rating scales need trained hands, and a placebo-heavy trial punishes weak site selection. Score two or three candidates against the same written scope and weight the items below over headline price.

• Therapeutic-area experience: ask for completed programs in your specific indication (Alzheimer's, Parkinson's, epilepsy, ALS, MS, migraine, neuropathic pain, depression, schizophrenia), not just "CNS" in general. The right neurodegeneration model is different from the right epilepsy model.
• Relevant disease models and brain-exposure capability: confirm the in vivo model is already validated in-house with historical control data, and that they run CNS-specific DMPK (brain-to-plasma, unbound brain concentration, CSF sampling, P-gp efflux, microdialysis) rather than plasma PK alone.
• Biomarker and imaging access: for clinical work, check they can run or coordinate CSF biomarkers (amyloid, tau, p-tau, NfL) and PET or MRI imaging cores, with validated assays and harmonized reference ranges across sites.
• Rater training and endpoint quality: subjective scales (ADAS-Cog, UPDRS, EDSS, MADRS) live or die on rater certification and central review. Ask how they train, certify, and monitor raters to control variability and placebo response.
• Patient access and site network: CNS enrollment is slow, especially in rare neuromuscular and pediatric neurology indications. Confirm real access to qualified sites, investigators, and patient populations in your geographies, and a credible feasibility track record.
• Regulatory track record and data quality: ask for FDA, EMA, or PMDA inspection history, CDISC-conformant data delivery (SDTM and ADaM), and GLP status for pivotal safety work. Seizure liability and neurobehavioral findings draw reviewer scrutiny, so clean, defensible data matters.
• Capacity and turnaround: a strong lab booked solid can be slower than a good lab with an open slot. Pin down current queue, the named study director or project lead, milestone timelines, and how they handle change orders when a cohort fails or enrollment slips.